The DREAM trial – Authors' reply - ScienceDirect

The Lancet

Volume 368, Issue 9552, 9–15 December 2006, Pages 2050-2051

The Lancet

https://doi.org/10.1016/S0140-6736(06)69829-2 Get rights and content

References (0)

Cited by (8)

A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study
2022, Diabetes, Obesity and Metabolism
Revisiting the Diabetes-Heart Failure Connection
2018, Current Diabetes Reports
Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males
2018, European Journal of Clinical Pharmacology
Anti-diabetic effect of magnesium salt extracts from deep-sea water in C57BLKS/J-db/db mice
2017, Applied Biological Chemistry
Early management of type 2 diabetes based on a SMBG strategy: The way to diabetes regression - The St Carlos study: A 3-year, prospective, randomized, clinic-based, interventional study with parallel groups
2013, Acta Diabetologica
Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes
2013, Current Diabetes Reports

View all citing articles on Scopus

Copyright © 2006 Elsevier Ltd. All rights reserved.